Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s): MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

CSE:MDMA - Post by User

Pharmala Biotech Holdings Inc > Halted

<< Previous

Bullboard Posts

Next >>

Comment by inviolablspiriton Mar 20, 2024 10:39pm

45 Views

Post# 35944199

RE:Halted

Absolutely fantastic news! I believe this may be the piece of the puzzle needed by Pharmala to form company partnerships. I think Nick needs the patent allowance first before closing any possible partnersip deals because without it, Pharmala's intelectual property is not protected.

I'm I reading this correctly?? And if this is the case, a signed partnership could be next?

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle